12:00 AM
 | 
Feb 03, 2003
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Notes 9/30 cash Years cash pre-cut 9 month operating loss
1/3/03 AeroGen (AEGN) 30% to 61 Also halted development of Aerodose insulin after it was unable to partner the product $14.8 0.5 $20.2
1/6/03 Deltagen (DGEN) 38% to 200 Discontinued all drug discovery programs to focus on discovery even by the end of 2003 subsidiaries in Utah and France. Hopes to break tools business. Also will divest. $49.7 0.6 $60.2
1/8/03 GeneScan...

Read the full 513 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >